We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

The Weight of Evidence on the Association of Isotretinoin Use and the Development of Inflammatory Bowel Disease

Cătălin Mihai Popescu, MD, PhD; Michael Bigby, MD
JAMA Dermatol. 2013;149(2):221-222. doi:10.1001/jamadermatol.2013.1348.
Text Size: A A A
Published online


An association between the use of isotretinoin and the development of inflammatory bowel disease (IBD) was first suggested by case reports that appeared shortly after isotretinoin was approved by the Food and Drug Administration for use in the United States in 1982.13 Whereas case reports and case series often provide the first and sometimes only evidence of adverse effects of drugs, they rarely provide definitive proof of association or causality and cannot be used to quantitate the risk.4 An adverse event can be attributed to a drug if it appears in an appropriate time after exposure, if other causes are excluded, and if it resolves when the drug is withdrawn and reappears on reexposure to the drug. These criteria are not met by case reports of isotretinoin and the development of IBD. Furthermore, in their analysis of available case reports, Crockett et al3 found that they did not fulfill the Hill criteria for causality or association and did not provide strong evidence of an association or causality.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles